The St. Louis facility was originally constructed in 1986 and has had recombinant biologics manufacturing on site since 1987. The facility, according to Centocor, is approved by the U.S. Food & Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA).
Centocor, a wholly owned subsidiary of Johnson & Johnson, is a biomedicines company involved in the research and development of treatments for a wide range of Immune-Mediated Inflammatory Disorders (I.M.I.D.), such as arthritis and inflammatory skin diseases, and for cancer. Its products are developed primarily through monoclonalantibody technology.